Rhythm Biosciences Limited (RHY.AX)
AUD 0.08
(-3.53%)
AUD 0.08
(-3.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 163.82 Thousand AUD | 93.63% |
| 2023 | 84.6 Thousand AUD | -50.27% |
| 2022 | 170.14 Thousand AUD | 0.0% |
| 2021 | - AUD | -100.0% |
| 2020 | 42.43 Thousand AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| 2018 | - AUD | 0.0% |
| 2017 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 38.93 Thousand AUD | 0.0% |
| 2024 Q4 | 163.82 Thousand AUD | 0.0% |
| 2024 FY | 163.82 Thousand AUD | 93.63% |
| 2023 FY | 84.6 Thousand AUD | -50.27% |
| 2023 Q2 | 128.01 Thousand AUD | 0.0% |
| 2023 Q4 | 84.6 Thousand AUD | 0.0% |
| 2022 Q4 | 170.14 Thousand AUD | 0.0% |
| 2022 FY | 170.14 Thousand AUD | 0.0% |
| 2022 Q2 | - AUD | 0.0% |
| 2021 Q2 | 10.73 Thousand AUD | 0.0% |
| 2021 FY | - AUD | -100.0% |
| 2021 Q4 | - AUD | 0.0% |
| 2020 Q4 | 42.43 Thousand AUD | 0.0% |
| 2020 FY | 42.43 Thousand AUD | 0.0% |
| 2020 Q2 | 130.71 Thousand AUD | 0.0% |
| 2019 Q4 | - AUD | 0.0% |
| 2019 Q2 | 78.49 Thousand AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 FY | - AUD | 0.0% |
| 2018 Q2 | - AUD | 0.0% |
| 2017 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Australian Clinical Labs Limited | 308.89 Million AUD | 99.947% |
| BCAL Diagnostics Limited | 641.34 Thousand AUD | 74.456% |
| Genetic Signatures Limited | 1.22 Million AUD | 86.583% |
| Genetic Technologies Limited | 643.54 Thousand AUD | 74.544% |
| Healius Limited | 1.59 Billion AUD | 99.99% |
| Imagion Biosystems Limited | 6.03 Million AUD | 97.287% |
| Integral Diagnostics Limited | 357.79 Million AUD | 99.954% |
| INOVIQ Ltd | 535.05 Thousand AUD | 69.382% |
| Microba Life Sciences Limited | 395.38 Thousand AUD | 58.567% |
| Monash IVF Group Limited | 59.56 Million AUD | 99.725% |
| Sonic Healthcare Limited | 4.51 Billion AUD | 99.996% |